The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Preclinical Evidence for the Use of Brexpiprazole + Antidepressant Treatment for Major Depressive Disorder and Post-Traumatic Stress Disorder: A Systematic Review
Open accessAbstract
Purpose: Brexpiprazole, when administered with antidepressant therapy, may provide additional benefits due to complementary actions on noradrenaline (norepinephrine), serotonin, and dopamine neurotransmitter systems. This review addressed the question: what information can preclinical studies provide on the use of brexpiprazole + antidepressant treatment? Methods: A systematic literature review was conducted to search for preclinical studies of brexpiprazole + antidepressant therapy that included a behavioral test relating to any psychiatric disorder. Ovid MEDLINE, Ovid Embase, and conference abstracts were searched (January 1, 2011–July 5, 2021). The statistically significant (p< 0.05) findings for brexpiprazole + antidepressant were extracted. Results: Of 296 records screened, nine articles were eligible, describing seven unique studies. In rodent models, including three models of depression (unpredictable chronic mild stress, social defeat stress, and lipopolysaccharide-induced depression), brexpiprazole + selective serotonin reuptake inhibitor (SSRI) or serotonin–noradrenaline reuptake inhibitor (SNRI) consistently showed statistically significant benefits over vehicle on depression-like behaviors (forced swim test, tail suspension test, sucrose preference), whereas brexpiprazole and antidepressant monotherapies did not. In the predator scent stress model of post-traumatic stress disorder (PTSD), brexpiprazole + SSRI (escitalopram) showed a significant benefit over vehicle and/or monotherapy on anxiety-like behaviors (elevated plus-maze) and hyperalertness (acoustic startle response), whereas brexpiprazole and escitalopram monotherapies did not significantly differ from vehicle. In the fear conditioning model of PTSD, brexpiprazole showed significant improvements whether administered as monotherapy or in combination with escitalopram. Conclusion: Based on a small number of studies, the administration of brexpiprazole with an antidepressant appears to have a greater treatment effect than either brexpiprazole or antidepressant monotherapies in preclinical studies of depression- and PTSD-like behaviors. Thus, preclinical studies support evidence from randomized clinical trials for the therapeutic effects of adjunctive brexpiprazole in the treatment of major depressive disorder, and brexpiprazole in combination with sertraline in the treatment of PTSD. Funding: Otsuka/Lundbeck. Plain Language Summary: Studies of medications in animals can provide additional information to complement studies in humans. This review investigates what can be learned from animal studies of brexpiprazole (a medication known as an “atypical antipsychotic”) given together with an antidepressant medication. Seven animal studies that assess brexpiprazole + antidepressant treatment in rat or mouse models of depression and post-traumatic stress disorder were identified. Overall, these animal studies provide support for the observed benefits of brexpiprazole added to antidepressant treatment in major depressive disorder, and the ongoing development of brexpiprazole + antidepressant as a potential combination treatment for post-traumatic stress disorder. Keywords: antidepressants, antipsychotics, depression, PTSD, behavior rating scale
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“case series combining brexpiprazole with ketamine or esketamine suggest rapid clinical recovery in complex presentations and motivate controlled multimodal trials [388].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [388]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n160 · Cited by 13,262 · cited 2×
“55 In Study 1, 25 marbles were evenly spaced on a layer of sawdust in a cage, and the number of marbles more than two thirds covered by sawdust after 30 minutes was counted, 28,29 where a lower number of buried marbles indicates a stronger therapeutic effect.”
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(85)90031-7 · Cited by 5,822
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
SYRCLE’s risk of bias tool for animal studies
Hooijmans, C. R., Rovers, M. M., de Vries, R. B., Leenaars, M., Ritskes-Hoitinga, M., & Langendam, M. W. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-43 · Cited by 4,415
Behavioral despair in mice: a primary screening test for antidepressants.
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977) · PubMed · Cited by 3,320
Behavioural despair in rats: A new model sensitive to antidepressant treatments
Porsolt, R. D., Anton, G., Blavet, N., & Jalfre, M. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90118-8 · Cited by 3,138
Willner, P., Towell, A., Sampson, D., Sophokleous, S., & Muscat, R. (1987) · Psychopharmacology · doi:10.1007/bf00187257 · Cited by 1,993
A standardized protocol for repeated social defeat stress in mice
Golden, S. A., Covington, H. E., Berton, O., & Russo, S. J. (2011) · Nature Protocols · doi:10.1038/nprot.2011.361 · Cited by 1,581
Chronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160 · cited 2×
“39,40 In the SDS model, C57BL/6 mice are repeatedly exposed to larger CD1 mice that have been screened for aggressive behavior.”
Cryan, J. F., Valentino, R. J., & Lucki, I. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.008 · Cited by 1,119
Research works printed but not linked: 7
- 2013, Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
- Hitzemann, 2000, Alcohol Res Health, 24, 149
- Maeda K, Stensbøl TB, Akazawa H, et al. Pharmacological profile of brexpiprazole (OPC-34712): a novel serotonin–dopamine activity modulator. Poster presented at: American Psychiatric Association 167th Annual Meeting; 2014; New York, NY. Available from: https://www.psychiatry.org/Psychiatrists/Search-Directories-Databases/Conference-Publications/2014/2014-Annual-Meeting-Posters-New-Research-Abstracts. Accessed August 3, 2024.
- Lerdrup L, Maeda K, Stensbøl TB. Brexpiprazole shows antidepressant- and anxiolytic-like effects in the rat forced swim and Vogel conflict tests. Poster presented at: American Psychiatric Association 168th Annual Meeting; 2015; Toronto, Canada. Available from: https://www.psychiatry.org/Psychiatrists/Search-Directories-Databases/Conference-Publications/2015/2015-Annual-Meeting-Posters-New-Research-Abstracts. Accessed August 3, 2024.
- Porsolt, 1977, Arch Int Pharmacodyn Ther, 229, 327
- 2009, Methods of Behavior Analysis in Neuroscience
- 2015, Fluoxetine: Pharmacology, Mechanisms of Action and Potential Side Effects
Cited by
Mechanisms of flame retardant toxicity and their impacts on anxiety and cognition in the brain
Rojas, C. M., Wiersielis, K. R., & Roepke, T. A. (2025) · Endocrinology · doi:10.1210/endocr/bqaf074 · Cited by 10
Stroud, J., Cummings, J. L., Chumki, S. R., Such, P., Wang, D., Palma, A. M., Zhang, Z., Brubaker, M., & Grossberg, G. T. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2552278 · Cited by 10
Self-citationAlissa, M., Alghamdi, S. A., Binshaya, A. S., Juraybi, T. N., Safhi, A. Y., Albati, A. A., Abalkhail, A., & Alqarni, A. M. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103340 · Cited by 2
Kotochinsky, M., Alessi, M. R., Vieira, G. H., Balogun, M., Sherpa, N. N., & Lezana, A. G. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.10.063 · Cited by 1
Danek, P. J., Pukło, R., & Daniel, W. A. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00859-1 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Brexpiprazole With Antidepressants for Agitation in Alzheimer’s Dementia: Post Hoc Analysis
Montano, C. B., Chumki, S. R., Wang, D., Palma, A. M., Zhang, Z., & Porsteinsson, A. P. (2026) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2026.06.015
Metadata
- Authors
- Brubaker, M., Kapadia, S., Maletic, V., Chambers, J., Watling, C., & Citrome, L.
- Affiliations
- Otsuka (United States) (US)
- University of South Carolina (US)
- New York Medical College (US)
- Corresponding author
- Brubaker, Malaak
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2025-02
- Volume
- Volume 21
- Pages
- 421-436
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC11878111
- OpenAlex
- W4408033871
- Cited by
- 7
- References
- 98
- Citations by year
- 2026: 4 · 2025: 3
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (acceptedVersion, other-oa)
- Touro Scholar (Touro College) (submittedVersion, cc-by-nc)
- Funders
- Otsuka Pharmaceutical
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- brexpiprazole, major depressive disorder, post-traumatic stress disorder, antidepressant combination therapy, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, escitalopram, sertraline, rodent models of depression, social defeat stress, chronic unpredictable mild stress, lipopolysaccharide-induced depression, fear conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
